TNFRSF1B and cardiovascular disorder: In patients with T2DM, established cardiovascular disease, eGFR > 30 mL/min/1.73 m2, and micro- or macroalbuminuria, Sen et al. [10] noted that canagliflozin was able to reduce the levels of circulating TNFR-1 and TNFR-2 by 2.8% (95% CI: 3.4–1.3) and 1.9% (95% CI: 3.2–0.2), respectively, leading to a lower risk of kidney outcome at year 1.